|
AU2013202322A1
|
|
Oligonucleotide analogs having cationic intersubunit linkages
|
|
AU2013202117A1
|
|
Antisense antiviral compound and method for treating influenza viral infection
|
|
CN103619356A
|
|
Peptide oligonucleotide conjugates
|
|
US2011269665A1
|
|
Compound and method for treating myotonic dystrophy
|
|
BR112012011381A2
|
|
isolated antiviral antisense oligonucleotide and pharmaceutical composition comprising the same
|
|
CA2746508A1
|
|
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
|
CA2742281A1
|
|
Immunosuppression compound and treatment method
|
|
US2010016215A1
|
|
Compound and method for treating myotonic dystrophy
|
|
CA2704261A1
|
|
Method of synthesis of morpholino oligomers
|
|
US2009105139A1
|
|
Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
|
|
US2008199961A1
|
|
ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
|
|
AU2007202366A1
|
|
Transforming growth factor beta (TGF-B) blocking agent-treated stem cell composition and method
|
|
CA2651881A1
|
|
Oligonucleotide analogs having cationic intersubunit linkages
|
|
CA2644262A1
|
|
Antisense antiviral compound and method for treating arenavirus infection
|
|
EP1937278A2
|
|
Antisense antiviral compound and method for treating picornavirus infection
|
|
WO2007030691A2
|
|
Antisense antiviral compound and method for treating picornavirus infection
|
|
US2007135333A1
|
|
Antisense antibacterial method and compound
|
|
WO2006121951A2
|
|
Antisense antiviral compounds and methods for treating foot and mouth disease
|
|
WO2006105479A2
|
|
Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
|
|
US2006205693A1
|
|
Antisense antiviral compounds and methods for treating a filovirus infection
|
